Edgewater Tech concludes review of strategic options with decision to go it alone

Edgewater Technology Inc. said Monday it has finished a review of its strategic options and concluded that it is best to remain a standalone company. The consulting firm said it held talks with multiple parties regarding various alternatives. “Ultimately, the board unanimously determined that continuing to focus on the company’s strategic plan provides the best opportunity to enhance value for our stockholders,” Wayne Wilson, independent director said in a statement. Edgewater shares were not yet active in premarket trade, but are down 0.1% in the year to date, while the S&P 500 has gained 6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Harman’s stock surges toward 1-year high after Samsung buyout bid

Shares of Harman International Industries Inc. soared 26% in premarket trade toward a one-year high Monday, after the auto parts maker agreed to be acquired by South Korea’s Samsung Electronics Co. Ltd. ina deal valued at about $8 billion. The stock was on track to open at the highest level since Nov. 6, 2015, but was 1.4% below the buyout bid of $112. If the gain holds, it would be the stock’s biggest one-day percentage jump, and the second-biggest price rally, since it went public in November 1986. The stock has lost 7% year to date through Friday, while the S&P 500 has gained 5.9%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Ocular Therapeutix surges 14% on positive early clinical trial results

Ocular Therapeutix Inc. shares surged as much as 13.5% in pre-market trade Monday after the company said its eye treatment had positive topline results in a late-stage clinical trial. The company said Dextenza, an insert intended to treat eye inflammation and pain after surgery, met primary efficacy endpoints for both. Dextenza failed to get Food and Drug Administration approval in late July, but Ocular said it planned to resubmit its application with the agency by the end of the year and would file for a post-surgical eye pain indication if approved. Ocular shares dropped 26.7% year-to-date, compared with a 5.9% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Dynavax’s stock plunges after disappointing FDA response to Hep-B treatment

Shares of Dynavax Technologies Corp. plunged 71% toward an eight-year low in premarket trade Monday, after the Food and Drug Administration didn’t approve its Hepatitis B treatment. The company said it received a complete response letter (CRL), which means the FDA completed its review but is requesting additional information, regarding its biologics license application (BLA) for Heplisav-B for adults. The “several” topics that CRL requests information on includes clarification regarding specific adverse events of special interest, a numerical imbalance in some cardiac events and analysis of the integrated safety data base across different time periods. “The CRL is consistent with our opinion that HEPLISAV-B is approvable and we are seeking to meet with the FDA as soon as possible,” said Chief Executive Eddie Gray. “However, the time and resources that will be required to gain approval leads us to consider that we may not be able to advance this program on our own and we are moving swiftly to identify a potential pharmaceutical or financial partner.” The stock has tumbled 52% year to date through Friday, while the S&P 500 has gained 5.9%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Corbus Pharmaceuticals stock more than doubles after positive drug trial results

Shares of Corbus Pharmaceuticals Holdings Inc. more than doubled in premarket trade Monday, after the drug maker announced positive results from a trial of its treatment for systemic connective tissue disease. A Phase 2 trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis was safe and met its efficacy endpoints. “The positive results of this study exceed our expectations and validate the unique mechanism of action of JBT-101,” said Chief Executive Yuval Cohen. “We look forward to the next stages in the clinical development of this drug.” The stock soared 114% toward the highest price seen since the company went public in late 2014. It has rocketed nearly 4 fold so far this year, while the SPDR S&P Pharmaceuticals ETF has tumbled 19% and the S&P 500 has gained 5.9%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Ventas to sell 36 nursing facilities to Kindred Healthcare for $700 million

Ventas Inc. announced Monday a deal to sell 36 skilled nursing facilities it owns, and operated by Kindred Healthcare Inc. , to Kindred for $700 million. The deal is part of Kindred’s previously announced plan to exit its skilled nursing facilities (SNF) business, or renew the current lease on all unpurchased SNFs through 2025 at current rent levels. For the SNFs Kindred operates but doesn’t buy from Ventas by April 30, 2018, the leases will be automatically renewed at current rates. Ventas will record a gain of over $600 million if the deal is completed, but there is no assurance of when the deal will close, if it closes. Neither stock was active in premarket trade. Year to date, Kindred’s stock has tumbled 45%, Ventas shares have gained 4.1%, the SPDR Health Care Select Sector ETF has slipped 2.1% and the S&P 500 has tacked on 5.9%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Caerus Investors sends letter to Kate Spade urging company to pursue a sale

New York-based activist investor Caerus Investors has sent a letter to the management of luxury handbag and accessories maker Kate Spade urging the company to pursue a sale of the company. The investor says it is deeply concerned about the decline in the company’s share price of the last two and half years and of the company’s inability to achieve the profit margins of its peers. “Given the market’s lack of faith in the current management team, as evidenced by the 63% decline in the shares since the intraday high on August 11th, 2014, we believe the best path for enhancing shareholder value is to pursue a sale of the company,” said the letter. “We strongly believe that a strategic, industry player would be willing to pay a substantial premium to add this growth business to their portfolio.” Caerus said it first invested in the company under then parent Liz Claiborne in 2009, on the basis that Kate Spade was mispriced inside a company with other assets that were underperforming and argued for a breakup of that company, which came in 2013. The stock rose above $40 the following year. “Since those successful moves, material shareholder value has been destroyed by wasting time, energy and money on the former sub brand Kate Spade Saturday and management has missed interim sales and margin targets on 3 different occasions,” said the letter. Kate Spade shares were not yet active in premarket trade, but are down 6.5% in the year to date, while the S&P 500 has gained 6%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Siemens agrees to buy U.S.-based Mentor in $4.5 billion deal

Siemens AG said Monday it has agreed to buy U.S.-based Mentor Graphics Corp. in a merger deal worth $4.5 billion. The German engineering company will pay $37.25 in cash for each share of Mentor, which makes software for automating the design of chips, boards and other electronic products. The offer price is a 21% premium to Mentor’s closing share price on Friday, the companies said in a joint statement. Mentor’s board of directors is recommending the approval of the merger, they said, and key Mentor shareholder Elliott Management has committed to supporting the deal. Siemens shares rose 1.3% in early trade, while Mentor shares were inactive in early premarket trading.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Digi International soars as Belden discloses $380 million buyout offer

Shares of Digi International Inc. soared in Friday’s extended session after Belden Inc. made public its proposal to buy the modem company for $13.82 a share. The all-cash deal values Digi at around $380 million. Belden had initially approached Digi last week but was rebuffed. In disclosing its offer, Belden is appealing directly to Digi’s shareholders to persuade them of the “compelling strategic fit inherent in a combination of the two companies.” Shares of Digi finished at $11.65 a share on Friday and surged 21% after hours. Belden’s stock was flat after closing at $69.70.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

6.2-magnitude earthquake strikes Japan

An earthquake measuring 6.2 on the Richter scale struck about 250 miles north of Tokyo early Saturday local time on Japan’s east coast, the U.S. Geological Survey said. The quake was centered in Ishinomaki, in the same vicinity as the devastating Tohoku earthquake that claimed thousands of lives in 2011. No tsunami warning has been issued at this time.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News